IDG-Accel China Growth Fund III Associates’s CASI Pharmaceuticals CASI Stock Holding History

IDG-Accel China Growth Fund III Associates’s Portfolio CASI Stock Details CASI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$9.49M	Hold	797,354	–	–	30.38%	2
2021 Q2	$12.4M	Hold	797,354	–	–	22.48%	2
2021 Q1	$19.1M	Hold	797,354	–	–	25.8%	2
2020 Q4	$23.5M	Hold	797,354	–	–	27.18%	2
2020 Q3	$12.2M	Hold	797,354	–	–	22.2%	2
2020 Q2	$19.9M	Hold	797,354	–	–	16.36%	2
2020 Q1	$16.3M	Hold	797,354	–	–	8.6%	3
2019 Q4	$24.6M	Buy	+797,354	New	+$25.9M	8.78%	3

Other funds holding CASI

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WSCM

Wellington Shields Capital Management New York $666M AUM 45.43% 1-Year Est. Return

WSC

Wellington Shields & Co New York $392M AUM 30.65% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

IDG-Accel China Growth Fund III Associates's CASI Position: Q3 2021 in Review

IDG-Accel China Growth Fund III Associates held its CASI Pharmaceuticals (CASI) position steady in Q3 2021 at 797,354 shares worth $9.49M. The position accounts for 30.38% of the portfolio, ranked #2.

IDG-Accel China Growth Fund III Associates first reported a position in CASI in Q4 2019 and has held it in 8 quarters since. The position peaked at $24.6M in Q4 2019. 58 funds tracked by Wall St. Rank hold CASI as of Q3 2021.

IDG-Accel China Growth Fund III Associates held 797,354 shares of CASI Pharmaceuticals worth $9.49M as of Q3 2021.
IDG-Accel China Growth Fund III Associates left its CASI Pharmaceuticals share count unchanged in Q3 2021.
CASI Pharmaceuticals made up 30.38% of IDG-Accel China Growth Fund III Associates's portfolio in Q3 2021, its #2 holding.
IDG-Accel China Growth Fund III Associates first reported a position in CASI Pharmaceuticals in Q4 2019 and has held it in 8 quarters since.
IDG-Accel China Growth Fund III Associates's CASI Pharmaceuticals position peaked at $24.6M in Q4 2019.
58 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q3 2021.

Based on IDG-Accel China Growth Fund III Associates's 13F filing for Q3 2021, filed 15 Nov 2021.